- $1.71bn
- $1.50bn
- $69.65m
Brief: Personalis And Tempus Announce Expanded Collaboration
Personalis Inc reports results for the quarter ended in January - Earnings Summary
Brief: Personalis Q2 Net Income USD -12.802 Million
Brief: Tempus AI Reports 15.1% Stake In Personalis As Of July 3, 2024-SEC Filing
Brief: Ravi Mhatre Says Will Seek To Engage In Dialogue With Personalis' Board
Brief: Personalis Inc - Personalis And Foresight Diagnostics Entered Into A Settlement And License Agreement
Brief: Personalis Provides Dial-In And Updated Date For ASCO Highlights Conference Call
Brief: Personalis Announces Start Of Cancer MRD Testing Commercialization Collaboration With Tempus
Brief: Personalis Announces Inducement Grants Under Nasdaq Listing Rule
Personalis Inc reports results for the quarter ended in January - Earnings Summary
Brief: Personalis Q1 Net Income USD -12.968 Million
Personalis Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Personalis Inc reports results for the quarter ended in December - Earnings Summary
Brief: Personalis Q4 Net Income USD -26.584 Million
Personalis Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Personalis And Clearnote Health Announce Partnership To Advance Epigenomic Technology
Brief: Personalis Announces Medicare Coverage For NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
Brief: Personalis Reports Preliminary Q4 And FY2023 Revenue And Cash Balance